Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
Parolia A, Eyunni S, Verma BK, Young E, Liu L, George J, Aras S, Das CK, Mannan R, Rasool RU, Luo J, Carson SE, Mitchell-Velasquez E, Liu Y, Xiao L, Gajjala PR, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Alhusayan M, Cao X, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. Parolia A, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 29:2024.02.22.581560. doi: 10.1101/2024.02.22.581560. bioRxiv. 2024. PMID: 38464251 Free PMC article. Preprint.
Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies.
He T, Xiao L, Qiao Y, Klingbeil O, Young E, Wu XS, Mannan R, Mahapatra S, Eyunni S, Tien JC, Wang X, Zheng Y, Kim N, Zheng H, Hou S, Su F, Miner SJ, Mehra R, Cao X, Sekhar AC, Samajdar S, Ramachandra M, Parolia A, Vakoc CR, Chinnaiyan AM. He T, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Jan 25:2024.01.22.576669. doi: 10.1101/2024.01.22.576669. bioRxiv. 2024. PMID: 38328238 Free PMC article. Preprint.
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
He T, Cheng C, Qiao Y, Cho H, Young E, Mannan R, Mahapatra S, Miner SJ, Zheng Y, Kim N, Zeng VZ, Wisniewski JP, Hou S, Jackson B, Cao X, Su F, Wang R, Chang Y, Kuila B, Mukherjee S, Dukare S, Aithal KB, D S S, Abbineni C, Lyssiotis CA, Parolia A, Xiao L, Chinnaiyan AM. He T, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 2:2024.02.29.582768. doi: 10.1101/2024.02.29.582768. bioRxiv. 2024. PMID: 38464081 Free PMC article. Updated. Preprint.
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Lord CJ, Ding K, Chinnaiyan AM. Tien JC, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 21:2024.03.20.585990. doi: 10.1101/2024.03.20.585990. bioRxiv. 2024. PMID: 38562774 Free PMC article. Preprint.
Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer.
Cheng C, Hu J, Mannan R, Bhattacharyya R, Rossiter NJ, Magnuson B, Wisniewski JP, Zheng Y, Xiao L, Li C, Awad D, He T, Bao Y, Zhang Y, Cao X, Wang Z, Mehra R, Morlacchi P, Sahai V, di Magliano MP, Shah YM, Ding K, Qiao Y, Lyssiotis CA, Chinnaiyan AM. Cheng C, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 20:2024.03.18.585580. doi: 10.1101/2024.03.18.585580. bioRxiv. 2024. PMID: 38562800 Free PMC article. Preprint.
p300/CBP degradation is required to disable the active AR enhanceosome in prostate cancer.
Luo J, Chen Z, Qiao Y, Ching-Yi Tien J, Young E, Mannan R, Mahapatra S, He T, Eyunni S, Zhang Y, Zheng Y, Su F, Cao X, Wang R, Cheng Y, Seri R, George J, Shahine M, Miner SJ, Vaishampayan U, Wang M, Wang S, Parolia A, Chinnaiyan AM. Luo J, et al. Among authors: mannan r. bioRxiv [Preprint]. 2024 Mar 30:2024.03.29.587346. doi: 10.1101/2024.03.29.587346. bioRxiv. 2024. PMID: 38586029 Free PMC article. Preprint.
Comprehensive proteogenomic characterization of rare kidney tumors.
Li GX, Chen L, Hsiao Y, Mannan R, Zhang Y, Luo J, Petralia F, Cho H, Hosseini N, Leprevost FDV, Calinawan A, Li Y, Anand S, Dagar A, Geffen Y, Kumar-Sinha C, Chugh S, Le A, Ponce S, Guo S, Zhang C, Schnaubelt M, Al Deen NN, Chen F, Caravan W, Houston A, Hopkins A, Newton CJ, Wang X, Polasky DA, Haynes S, Yu F, Jing X, Chen S, Robles AI, Mesri M, Thiagarajan M, An E, Getz GA, Linehan WM, Hostetter G, Jewell SD, Chan DW, Wang P, Omenn GS, Mehra R, Ricketts CJ, Ding L, Chinnaiyan AM, Cieslik MP, Dhanasekaran SM, Zhang H, Nesvizhskii AI; Clinical Proteomic Tumor Analysis Consortium. Li GX, et al. Among authors: mannan r. Cell Rep Med. 2024 May 21;5(5):101547. doi: 10.1016/j.xcrm.2024.101547. Epub 2024 May 3. Cell Rep Med. 2024. PMID: 38703764 Free article.
Deciphering intratumor heterogeneity in clear cell renal cell carcinoma utilizing clinicopathologic and molecular platforms.
Vormittag-Nocito E, Mannan R, Wang X, Chinnaiyan A, Zhang Y, Zelenka-Wang S, Cao X, Morgan TM, Hafez K, Vaishampayan U, Abdulfatah E, Chinnaiyan AM, Dhanasekaran SM, Mehra R. Vormittag-Nocito E, et al. Among authors: mannan r. Hum Pathol. 2022 Dec;130:95-109. doi: 10.1016/j.humpath.2022.10.009. Epub 2022 Oct 27. Hum Pathol. 2022. PMID: 36511267
152 results